Byrna Technologies (NASDAQ:BYRN) reported quarterly sales of $12.40 million which missed the analyst consensus estimate of $13.88 million by 10.66 percent. This is a 42.48 percent increase over sales of $8.70 million the same period last year.
Windtree Therapeutics Announces Publication From Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders of acute heart
